Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Shares of Acceleron Pharma Rocketed Higher Today

By Brian Orelli, PhD - Updated Jan 28, 2020 at 11:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A successful midstage clinical trial has investors giddy, but the devil will be in the details.

What happened

Shares of Acceleron Pharma (XLRN) are up 41% at 11:19 a.m. EST following a report after the closing bell yesterday that the company's heart drug sotatercept was successful in a phase 2 clinical trial in patients with pulmonary arterial hypertension (PAH), a disease characterized by high blood pressure in the lungs.

So what

After 24 weeks of treatment, sotatercept was able to reduce pulmonary vascular resistance (PVR), the primary endpoint of the study. PVR measures the severity of PAH. The drug also improved secondary endpoints including how far the patients could walk in six minutes (6MWD) as well as two other measures of PAH severity: N-terminal pro b-type natriuretic peptide levels and World Health Organization (WHO) functional class.

Acceleron Pharma didn't put any numbers to the successful endpoints. As drug companies often do, it's saving the data for a medical meeting later this year.

But the company did note that the study was "powered to detect an 18% reduction in the primary endpoint of PVR and a 24-meter improvement in the secondary endpoint of 6MWD," so the drug likely met those goals.

Doctor showing a patient a chest x-ray

Image source: Getty Images.

Now what

The presentation of the actual data will be important in determining the likelihood of success in a phase 3 study. In addition to the magnitude of improvement in PVR and 6MWD, investors should be looking for a dose response with which a higher dose produces better results than a lower dose. The efficacy of sotatercept in the different WHO functional classes -- whether it helps all patients or just the sickest patients, for example -- will also help determine the drug's potential if it makes it to market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acceleron Pharma Stock Quote
Acceleron Pharma

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.